-
Mashup Score: 0Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates | Moderna, Inc. - 3 year(s) ago
Moderna COVID-19 Vaccine mRNA-1273: Final blinded analysis of Phase 3 COVE study shows 93% efficacy; Efficacy remains durable through six months after second dose Moderna booster candidates demonstrate robust antibody responses to COVID-19 variants of concern in Phase 2 Dosing started in Phase 1
Source: Moderna, Inc.Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 406Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine | Moderna, Inc. - 3 year(s) ago
mRNA-1010 is Moderna’s first seasonal influenza vaccine candidate to enter the clinic mRNA-1010 is a quadrivalent seasonal influenza vaccine candidate targeting WHO recommendations including A H1N1, H3N2 and influenza B Yamagata and Victoria lineages Moderna’s vision is to develop a respiratory
Source: Moderna, Inc.Categories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 2Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine | Moderna, Inc. - 3 year(s) ago
mRNA-1010 is Moderna’s first seasonal influenza vaccine candidate to enter the clinic mRNA-1010 is a quadrivalent seasonal influenza vaccine candidate targeting WHO recommendations including A H1N1, H3N2 and influenza B Yamagata and Victoria lineages Moderna’s vision is to develop a respiratory
Source: Moderna, Inc.Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 13Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine | Moderna, Inc. - 3 year(s) ago
mRNA-1010 is Moderna’s first seasonal influenza vaccine candidate to enter the clinic mRNA-1010 is a quadrivalent seasonal influenza vaccine candidate targeting WHO recommendations including A H1N1, H3N2 and influenza B Yamagata and Victoria lineages Moderna’s vision is to develop a respiratory
Source: Moderna, Inc.Categories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 0Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine | Moderna, Inc. - 3 year(s) ago
mRNA-1010 is Moderna’s first seasonal influenza vaccine candidate to enter the clinic mRNA-1010 is a quadrivalent seasonal influenza vaccine candidate targeting WHO recommendations including A H1N1, H3N2 and influenza B Yamagata and Victoria lineages Moderna’s vision is to develop a respiratory
Source: Moderna, Inc.Categories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1
Serum samples from eight participants obtained one week after second dose of the primary series in the Phase 1 clinical trial of the Moderna COVID-19 Vaccine Serum neutralization assays performed on emerging variants including 2 additional versions of the Beta variant (B.1.351) and 3 lineage
Source: Moderna, Inc.Categories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 19
Serum samples from eight participants obtained one week after second dose of the primary series in the Phase 1 clinical trial of the Moderna COVID-19 Vaccine Serum neutralization assays performed on emerging variants including 2 additional versions of the Beta variant (B.1.351) and 3 lineage
Source: Moderna, Inc.Categories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 12Moderna Files for Emergency Use Authorization for its COVID-19 Vaccine in Adolescents in the United States | Moderna, Inc. - 3 year(s) ago
Submission based on Phase 2/3 study of mRNA-1273 in adolescents ages 12 to less than 18 in the U.S. CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jun. 10, 2021– Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has
Source: Moderna, Inc.Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5Moderna Files for Emergency Use Authorization for its COVID-19 Vaccine in Adolescents in the United States | Moderna, Inc. - 3 year(s) ago
Submission based on Phase 2/3 study of mRNA-1273 in adolescents ages 12 to less than 18 in the U.S. CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jun. 10, 2021– Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has
Source: Moderna, Inc.Categories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1
Primary endpoint of non-inferior immunogenicity versus the Phase 3 study adult comparator group was met No cases of COVID-19 observed after two doses of vaccine using the primary case definition, consistent with a vaccine efficacy of 100% Safety and tolerability generally consistent with Phase 3
Source: Moderna, Inc.Categories: Infectious Disease, Latest HeadlinesTweet
Moderna reports efficacy of their coronavirus vaccine through at least six months, however warns a booster shot may be required. https://t.co/mi03Qj7NXG